Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients
myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and…
Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy
myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL…
Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies
myCare-021-02 study discovers patient-specific resistance mechanisms that can inform…
Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with
Monosomy 7
myCare-021-04 study finds genetic signatures associated with 100% remission rate from…
myCare Clinical Studies Show Cellworks Singula™Achieves Superior Therapy Response Predictions for Brain Cancer Patients
Cellworks Multi-omics Biosimulation Delivers GBM and LGG Survival Predictors Above and…
Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments
myCare Studies Show Cellworks Multi-omics Biosimulation is a Superior Predictor of…
Cellworks Singula™ Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy
myCare Study Shows Cellworks Multi-omics Biosimulation is a Superior Predictor of…
Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy
Study Uses NGS Data with Biosimulation to Predict Drug Response in AML and MDS…
Cellworks myCare™ Clinical Trial Transforms NGS Data into Personalized Cancer Therapy Actions
New Trial Biosimulates Efficacy of Cancer Therapies Using Molecular Genetic Aberration…
Cellworks Study Predicted Non-Response to Azacitidine in MDS Patients with 100% Accuracy using AI-Driven Biosimulation
Analysis Uncovered Possible Mechanisms for AZA Resistance that could be Targeted to…
Cellworks AI-Driven Biosimulation Predicted Chemo-resistance in AML and MDS Patients with 90% Accuracy
Prospective Study Successfully Identified Mechanisms for AML…
Cellworks to Present 10 Abstracts at 2018 American Society of Hematology Annual Meeting
ASH Abstracts Reveal How AI-Driven Biosimulation Technology Predicts Drug Response in…
Former UnitedHealth Group Cancer Director Dr. Lee Newcomer Joins Cellworks Board of Directors
Leading Precision Medicine Company Adds to Prestigious Board of Directors, which…
Dr. Allen Lichter Joins Cellworks Group Board of Directors
Former CEO of ASCO Elected to Board of Leading Precision Medicine Company
…
Tackling the TB epidemic
LONDON—As tuberculosis drug sensitivity and resistance reaches epidemic proportions in…
Wellcome Trust supports collaboration to find new treatment for tuberculosis
The Wellcome Trust has supported a collaboration between AstraZeneca and Cellworks to…
AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
AstraZeneca and Cellworks today announced a collaboration supported by the Wellcome…
Predicting Pathway Effects
Drug development programs today have a 5% to 10% probability of success. Almost half…
Innovate while derisking drug development- yes we can!
The outlook for the drug industry continues to remain bleak in context of productivity…
Cellworks Taps Semiconductor Expertise to Boost Predictability
With $7.5 million of Series A funding in hand and a Series B round on deck, Cellworks…
Going for multiple shots on goal
As the first part of this series began with the single word, "Viagra," this…